Dalton Pharma Services, a contract provider of sterile manufacturing services, has signed a new service contract with Andes Biotechnologies to supply large molecule sterile dose manufacturing services for Phase I/II clinical trials. The agreement includes the cGMP sterile manufacturing of clinical materials which Dalton will perform in its recently upgraded cGMP sterile manufacturing facility, located in Toronto, Canada. Dalton will also be performing the transfer of analytical methods and analytical release testing of the product in its Health Canada approved laboratories.

Andes Biotechnologies, based in Santiago, Chile, was founded in 2008 and is focused on developing new anti-cancer therapies using the inactivation of non-coding mitochondrial RNA targets through antisense oligonucleotide technology.

Source: Dalton Pharma Services